SCYX יתרות המזומנים של החברה SCYNEXIS, Inc.

SCYNEXIS, Inc. (SCYX) revenues are based on Brexafemme sales and payments from GSK. The cash balance illustrates the resource dynamics for operating activities, where 0.05 is the current level of this metric. Stability is ensured by exclusive patents for next-generation antimycotics. Minimal geopolitical risks and operations within the US legal framework guarantee the protection of intellectual property.
SCYNEXIS, Inc. (SCYX) - פילוחי מדדים ודוחות פיננסיים

Fundamental asset selection requires precise liquidity monitoring to assess a business's ability to service its obligations without external financing. This indicator measures actual cash volume, determining the capital burn rate of SCYNEXIS, Inc. (SCYX) given its narrow specialization in a single platform, which allows for an assessment of the licensing model's sustainability via current cash reserves in the absence of operational growth.